What is Sipuleucel-T
Sipuleucel-T (Provenge or APC-8015) is an autologous cellular immunotherapy used for the treatment of prostate cancer.
Brand Name
Provenge
Indications & Dosage
- prostate cancer
For the treatment of asymptomatic or minimally symptomatic metastatic, castrate resistant (hormone refractory), prostate cancer
NOTE: Approximately 3 days prior to each infusion of sipuleucel-T, a standard leukapheresis procedure is to be done. If the patient is unable to receive an infusion of sipuleucel-T and treatment is to be continued, the patient will need to undergo an additional leukapheresis procedure.
NOTE: Prior to infusion of sipuleucel-T, match the patient’s identity with the patient identifiers on both the Cell Product Disposition Form and the sipuleucel-T infusion bag.
Side Effects
- anemia
- anorexia
- arthralgia
- asthenia
- back pain
- bone pain
- bronchospasm
- chills
- constipation
- cough
- diarrhea
- dizziness
- dyspnea
- fatigue
- fever
- headache
- hematuria
- hot flashes
- hyperhidrosis
- hypertension
- hypoxia
- infection
- influenza
- infusion-related reactions
- insomnia
- musculoskeletal pain
- myalgia
- nausea
- paresthesias
- peripheral edema
- rash
- stroke
- tremor
- vomiting
- weight loss
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- cardiac disease
- chemotherapy
- children
- immunosuppression
- infants
- infusion-related reactions
- neonates
- pregnancy
- pulmonary disease
Interactions
- Antithymocyte Globulin
- Azathioprine
- Basiliximab
- Clozapine
- Cyclosporine
- Dexamethasone
- Efalizumab
- Methylprednisolone
- Muromonab-CD3
- Prednisolone
- Prednisone
- Rituximab
- Rituximab; Hyaluronidase
